GGrantIndex
Sort

48,018 grants matching immunotherapy

Antibody Engineering Program

$588,522
Mitchell Ho · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

$588,460
James A Stewart · University Of Wisconsin-Madison · U10 · FY2007 · CA

HBV-specific T cell immunity in HBV/HIV coinfection

$588,450
Michael Jeffrey Vinikoor · University Of Alabama At Birmingham · R37 · FY2025 · AI

Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion

$588,394
Ioannis Vlachos · Beth Israel Deaconess Medical Center · R01 · FY2025 · CA

Embryonic natural killer cell development and function

$588,284
Christopher Michael Sturgeon · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · HL

Micro-nanotechnologies for the analysis of islet-derived extracellular vesicles implicated in Type 1 Diabetes

$588,253
Alphonsus Ng · Utah State Higher Education System--University Of Utah · R01 · FY2025 · DK

PD-1/PD-L1 modulation in cancer therapy

$588,135
Drew M. Pardoll · Johns Hopkins University · R01 · FY2022 · CA

Regulation of anti-tumor immunity by HDAC11

$588,117
Edward Seto · George Washington University · R01 · FY2021 · CA

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

$588,065
Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

$588,065
Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Targeting the host immune response during sepsis

$587,877
Guochang Hu · University Of Illinois At Chicago · R01 · FY2022 · HL

Targeting the host immune response during sepsis

$587,877
Guochang Hu · University Of Illinois At Chicago · R01 · FY2021 · HL

Immune cell control of ovarian cancer

$587,759
Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Advancing the translatability of mouse models for cancer immunotherapy

$587,737
Rosemary J Akhurst · University Of California, San Francisco · R01 · FY2018 · CA

Targeting Aldehyde Dehydrogenase for Cancer Prevention

$587,645
Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2023 · CA

Non-invasive imaging of the anti-tumor immune response

$587,640
Novalia Pishesha · Boston Children'S Hospital · R01 · FY2025 · CA

Proj 3 - Targeting the Pro-tumorigenic Microenvironment

$587,566
Yves A Declerck · Children'S Hosp Of Philadelphia · P01 · FY2020 · CA

Suppressing the Co-chaperone UNC45A reprograms the immunosuppressive tumor microenvironment to fight Cancer

$587,524
Ahmed Chadli · Augusta University · R01 · FY2025 · CA

Body composition and the obesity paradox in clear cell renal cell carcinoma

$587,431
Anna Helena Furberg-Barnes · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Data-driven inference of regulators for cytokine-mediated tumor killing

$587,416
Peng Jiang · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer

$587,394
Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2024 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES

$587,298
University Of Wisconsin Madison · U10 · FY2001 · CA

Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity

$587,283
Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2022 · CA

Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity

$587,283
Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2023 · CA

Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer.

$587,277
Rahul Suresh Shinde · Wistar Institute · R37 · FY2024 · CA